[HTML][HTML] S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis
…, B Hellmich, JU Holle, C Kneitz, I Kötter… - Zeitschrift für …, 2017 - Springer
Erstellt unter Federführung der Deutschen GesellschaftfürRheumatologie (DGRh) assoziierten
Vaskulitiden (AAV). Zu den ANCA-assoziierten Vaskulitiden zählen die Granulomatose …
Vaskulitiden (AAV). Zu den ANCA-assoziierten Vaskulitiden zählen die Granulomatose …
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
…, A Kotulska, C Denton, PC Coelho, I Kötter… - Annals of the …, 2010 - ard.bmj.com
Objectives To determine the causes and predictors of mortality in systemic sclerosis (SSc).
Methods Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria …
Methods Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria …
2018 update of the EULAR recommendations for the management of Behçet's syndrome
Several new treatment modalities with different mechanisms of action have been studied in
patients with Behçet’s syndrome (BS). The aim of the current effort was to update the …
patients with Behçet’s syndrome (BS). The aim of the current effort was to update the …
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial
…, AA Van De Loosdrecht, T Daikeler, I Kötter… - Jama, 2014 - jamanetwork.com
Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell
transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small …
transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small …
Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe
CC Zouboulis, I Kotter, D Djawari, W Kirch… - Yonsei medical …, 1997 - eymj.org
The German Registry of Adamantiades-BehÇet's disease was founded in 1990 in Berlin and
it provides current data on the epidemiology, the clinical manifestations and the course of …
it provides current data on the epidemiology, the clinical manifestations and the course of …
[HTML][HTML] DGRh-S2e-Leitlinie
…, J Rech, M Fleck, N Blank, JP Haas, I Kötter… - Zeitschrift für …, 2022 - Springer
5. Methodik Die methodischen Grundlagen der Leitlinienerstellung inklusive
Empfehlungserarbeitung mit Schlüsselfragen, Suchstrategien, Evidenz-und Biasbewertung sind im …
Empfehlungserarbeitung mit Schlüsselfragen, Suchstrategien, Evidenz-und Biasbewertung sind im …
[HTML][HTML] Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for …
…, J Van Laar, J Ouyang, T Kozak, J Moore, I Kötter… - …, 2010 - ncbi.nlm.nih.gov
Background Autologous hematopoietic stem cell transplantation has been used since 1996
for the treatment of severe autoimmune diseases refractory to approved therapies. We …
for the treatment of severe autoimmune diseases refractory to approved therapies. We …
Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis
I Kötter, M Zierhut, AK Eckstein, R Vonthein… - British Journal of …, 2003 - bjo.bmj.com
Background: Behçet's disease is a multisystem vasculitis of unknown origin. Standard
treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly …
treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly …
The use of interferon α in Behçet disease: review of the literature
I Kötter, I Günaydin, M Zierhut, N Stübiger - Seminars in arthritis and …, 2004 - Elsevier
OBJECTIVES: To evaluate the efficacy and safety of interferon (IFN) alpha for the treatment
of Behçet’s disease (BD) and discuss its possible mechanisms of action. METHODS: Reports …
of Behçet’s disease (BD) and discuss its possible mechanisms of action. METHODS: Reports …
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
Objectives Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease;
its management is largely empirical. This is the first clinical study to determine if interleukin (IL)…
its management is largely empirical. This is the first clinical study to determine if interleukin (IL)…